Supercede Therapeutics, Inc., a startup biotech company focused on small molecule drug development, today announced preclinical efficacy data from its lead therapeutic program to treat obesity.

Merck’s phase 3 HYPERION study of Winrevair meets primary endpoint in recently diagnosed adults with pulmonary arterial hypertension: Rahway, New Jersey Tuesday, June 24, 2025, ...

Topline results were announced from a phase 3 study evaluating sotatercept-csrk in recently diagnosed adults with pulmonary arterial hypertension (PAH).

Please note: If you switch to a different device, you may be asked to login again with only your ACS ID. Please note: If you switch to a different device, you may be ...

Panelists discuss how riociguat targets the nitric oxide pathway and is approved for both Group 1 PAH and Group 4 chronic ...

Follistatin-344 peptide has garnered significant attention in scientific research due to its intricate interactions with ...

Follistatin-344 (FS-344), a glycoprotein variant, has emerged as a focal point in scientific research due to its potential ...

The ZENITH study found that in high-risk PAH, add-on sotatercept was tied to lower risk for death from any cause, lung ...

本研究聚焦新生儿坏死性小肠结肠炎（NEC）的发病机制，揭示了Activin A通过激活ALK4-Smad2/3信号轴，加剧肠上皮细胞凋亡和屏障 ...

After a major shareholder pushed back, Keros is returning half of its capital to investors in a move that Guggenheim analysts ...

The myocardium consists of different cell types, of which endothelial cells, cardiomyocytes, and fibroblasts are the most abundant. Communication between these different cell types, also called ...